Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | HCK | P08631 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.46 |
| ▸ | PRKDC | P78527 | 2/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29829168 | 1.00 | OXER1 (0.50) | OXER1PIK3CDABL1EGFRHCK | |
| SCHEMBL4387826 | 0.88 | OXER1 (0.50) | OXER1PIK3CDABL1EGFRHCK | |
| SCHEMBL3269495 | 0.84 | PIK3CD (0.47) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1273077 | 0.84 | HTR6 (0.49) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL20096773 | 0.84 | HSP90AA1 (0.44) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL18805035 | 0.82 | PIK3CD (0.46) | PIK3CDABL1EGFRHCKSRC | |
| Methane SCHEMBL6390810 | 0.82 | HTR6 (0.48) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL819797 | 0.82 | PIK3CD (0.46) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL1454498 | 0.82 | PIK3CD (0.46) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL312329 | 0.82 | PIK3CD (0.51) | PIK3CDABL1EGFRHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753611-B1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-2753611-B1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20150246902-A1 | SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246902-A1 | SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150246902-A1 | SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2013034048-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034048-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| CN-102850324-A | Indole compounds | MICROBIA INC | 2013-01-02 | — | — | CN | disclosed |
| CN-1256324-C | Pyrrolidine derivatives as factor Xa inhibitors | GLAXO GROUP LTD (GB) | 2006-05-17 | — | — | CN | disclosed |
| US-20050107379-A1 | Pyrrolidine derivatives as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1395553-B1 | PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS | GLAXO GROUP LTD (GB) | 2005-02-16 | — | — | EP | disclosed |
| CN-1538955-A | Pyrrolidine derivatives as factor Xa inhibitors | — | 2004-10-20 | — | — | CN | disclosed |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | GLAXO GROUP LIMITED (GB) | 2004-08-05 | — | — | US | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| EP-1395606-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002100886-A1 | PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF FACTOR XA | GLAXO GROUP LIMITED (GB) | 2002-12-19 | — | — | WO | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | OXER1 128/4885PIK3CD 1681/4885ABL1 2833/4885 |
| US-20150246902-A1 | SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | EIF5B, EIF2AK2, HCCS | OXER1 3253/4885PIK3CD 4414/4885ABL1 549/4885 |
| US-20050107379-A1 | Pyrrolidine derivatives as factor xa inhibitors | TFPI, F2, SERPINC1 | OXER1 3235/4885PIK3CD 1901/4885ABL1 3388/4885 |
| US-20040152697-A1 | Pyrrolidin-2-one derivatives as inhibitors of factor xa | TFPI, SERPINC1, TFPI2 | OXER1 2270/4885PIK3CD 1417/4885ABL1 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.